The European Medicines Agency has begun reviewing a number of new medicines for potential pan-EU marketing approval, including lenacapavir, Gilead Sciences’ investigational, first-in-class, long-acting viral capsid inhibitor for treating HIV in people with limited therapy options.
If authorized, lenacapavir would be the first capsid inhibitor and the only HIV treatment option administered twice yearly, claims Gilead, which in June filed a marketing application for the product in the US
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?